EP1105379B1 - Wasserlösliche ähnliche verbindungen und medicament-vorstufe von paclitaxel - Google Patents

Wasserlösliche ähnliche verbindungen und medicament-vorstufe von paclitaxel Download PDF

Info

Publication number
EP1105379B1
EP1105379B1 EP98940677A EP98940677A EP1105379B1 EP 1105379 B1 EP1105379 B1 EP 1105379B1 EP 98940677 A EP98940677 A EP 98940677A EP 98940677 A EP98940677 A EP 98940677A EP 1105379 B1 EP1105379 B1 EP 1105379B1
Authority
EP
European Patent Office
Prior art keywords
paclitaxel
analogs
prodrugs
malyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP98940677A
Other languages
English (en)
French (fr)
Other versions
EP1105379A1 (de
Inventor
Peter Hermanus Gerardus Wiegerinck
Duncan Sperling
Lesly Braamer
Eric Wilhelmus Petrus Damen
Johan Wilhelm Scheeren
Dick De Vos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmachemie BV
Original Assignee
Pharmachemie BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmachemie BV filed Critical Pharmachemie BV
Publication of EP1105379A1 publication Critical patent/EP1105379A1/de
Application granted granted Critical
Publication of EP1105379B1 publication Critical patent/EP1105379B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to water soluble prodrugs in which the solubilizing groups are non toxic acids which are attached to paclitaxel as an ester functionality to the C2' and optionally C7-hydroxyl position.
  • These prodrugs are stable in aqueous solution but are readily hydrolyzed at physiological conditions to the parent drug.
  • Paclitaxel (1) is a natural diterpenoid, isolated from the Pacific yew tree ( Taxus brevifolia ). Paclitaxel has been approved for treatment of patients with advanced ovarian cancer or breast cancer.
  • paclitaxel Although paclitaxel has demonstrated to be an unique antitumor agent, it has several disadvantages.
  • One of the major problems is its poor solubility in water, which makes formulation difficult in relation to the intravenous administration. Due to this poor solubility, paclitaxel is formulated, using a 1:1 mixture of cremophor EL (a polyethoxylated castor oil) and ethanol (Rowinsky, E.K. et al. J. Natl. Cancer Inst . 1990, 82, 1247). This mixture is diluted with 5 % dextrose in water or saline prior to lengthy infusion.
  • Prodrug strategies consist of temporary modification of the physiochemical properties of a compound through chemical derivatization. Such temporary chemical modification is usually designed to alter aqueous solubility and biodistribution while the pharmacological properties of the parent drug remain intact.
  • Prodrugs can be designed to be converted in a predictable way, in vivo, to the active drug by either an enzymatic mechanism or by hydrolysis initiated under physiological pH conditions.
  • Chemical stability is critical to the formulation and storage of any water soluble analog/prodrug of paclitaxel, since partial degradation to the poorly soluble parent drug is likely to lead to precipitation of paclitaxel.
  • the enzymatic stability (in rat, human plasma or in vivo ) is important in relation to the degradation of the prodrugs to paclitaxel or to an active metabolite of paclitaxel.
  • a further object of this invention is to produce water soluble analogs of paclitaxel which possess ( in vitro or in vivo ) antitumor activity in the same extent as paclitaxel.
  • Figure 1 illustrates the protection of one of the carboxylic acids together with the ⁇ -hydroxyl group of malic acid (2) as an isopropylidene functionality, resulting in compound 3 .
  • this figure also the synthesis of 2'-malylpaclitaxel (5) , via coupling of 3 to the C2'-hydroxyl group of paclitaxel, leading to 4 , and removal of protective isopropylidine functionality, is presented. Finally it contains the conversion of 5 into the corresponding sodium salt 6 .
  • Figure 2 illustrates the synthesis of 2',7-bis(malyl)paclitaxel (8) , carried out similar to the synthesis of 5 .
  • the coupling reaction of 3 with paclitaxel, leading to 7 was carried out at 40 °C.
  • Figure 3 illustrates the synthesis of 7-malylpaclitaxel (11) , via 2'-Trocpaclitaxel (9) , which was coupled to 3 , leading to 10 , followed by removal of the protecting groups.
  • Paclitaxel was obtained from Pharmachemie BV Haarlem. Proton magnetic resonance spectra were measured on a Bruker AC-100 or a Bruker AM-400 spectrometer. Chemical shift values are reported as ⁇ -values relative to tetramethylsilane as an internal standard; deuterochloroform was used as solvent. Mass spectra were obtained with a double focusing VG 7070E spectrometer. Elemental analyses were carried out on a Carlo Erba Instruments CHNSO EA 1108 element analyzer. Melting points were determined with a Reichert Thermopan microscope and are uncorrected.
  • 1,2- O -(Propane-2,2-diyl)-malic acid (3) was obtained after treatment with malic acid (2) with acetone, in the presence of p -toluenesulfonic acid.
  • 2'-malylpaclitaxel (5) was synthesized by reaction of paclitaxel (1) with 1.1 equivalent of 3 in the presence of diisopropylcarbodiimide (DIPC) and 4-dimethylaminopyridine (DMAP) at 0 °C to afford 2'-(1,2- O -(propane-2,2-diyl)-malyl)-paclitaxel (4) , which reacted with a mixture of HOAc/THF/H 2 O : 4/1/2 at 45 °C to give 2'-malylpaclitaxel (5 ).
  • This compound 5 was subsequently eluted with a mixture of H 2 O/acetone : 4/1 (v/v) from DOWEX 50Wx2, pretreated with
  • 1,2- O -(Propane-2,2-diyl)-malic acid (3) was coupled to paclitaxel (1) in the presence of DIPC and DMAP at 40 °C to yield 2',7-bis(1,2- O -(propane-2,2-diyl)-malyl)-paclitaxel (7).
  • This compound 7 was converted to 2',7-bis(malyl)paclitaxel (8) by treatment with a mixture of HOAc/THF/H 2 O : 4/1/2.
  • Compound 8 can be further converted into for example sodium salts analogously to the procedure described for compound 6 .
  • Paclitaxel or paclitaxel prodrugs (5, 6, 8, 11) were suspended in water or PBS-buffer (pH 7.4) until a concentration was reached of 2 mg/ml. The suspensions were sonicated for 15 minutes and centrifuged (13000 g) for 10 minutes (Nicolaou, K.C. et al. Nature 1993, 364, 464-466). The above fluid was analyzed, using HPLC. The paclitaxel (prodrug) concentration was determined using paclitaxel standards in methanol.
  • HPLC Rheodyne injection valve (20 ⁇ l loop); Lichrospher 5RP18 column (200x3 mm, Chrompack); UV-detector (Model 759A, Applied Biosystems); eluent: CH 3 CN/MeOH/H 2 O : 5/1/4 in 10 mM NH 4 OAc (pH 5.0) (Willey, T.A. J. Chromatography 1993, 621, 231-238).
  • the detection of the (pro)drugs was performed at 226 nm, where it is supposed that the extinction coefficients of paclitaxel and paclitaxel prodrugs are equal. The concentrations were determined by measuring the relative area of paclitaxel or the paclitaxel prodrugs.
  • the paclitaxel prodrugs (5, 6, 8, 11,) were dissolved in water, sonicated and centrifuged. 100 ⁇ l of the above fluid was mixed with 400 ⁇ l of plasma (heparin) or PBS-buffer (pH7.4), respectively, in such way that the concentration of the prodrug was about 0.5 mg/mL.
  • the (pro)drugs were dissolved in 50 ⁇ l eluent and analyzed by HPLC (Longnecker, S.M. Cancer Treat Rep. 1987, 71, 53-59). The efficiency for the extraction of paclitaxel was about 80%.
  • MCF7 is estrogen receptor ER+/Progesterone receptor PgR+ and EVSA-T is ER-/PgR-.
  • a myocoplasma test was carried out on all cell lines and found to be negative. All cell lines, except ETSA-T, were maintained in a continuous logarithmic culture in RPMI medium with Hepes and Phenol red supplemented with 10 % bovine calf serum (BCS), penicillin 111 IU/ml, streptomycin 111 ⁇ g/ml, gentamycin 46 ⁇ g/ml and insulin 10.6 ⁇ g/ml. EVSA-T was maintained in DMEM with 5 % BCS and antibiotics as described. The cells were mildly trypsinized for passage and for use in experiments.
  • BCS bovine calf serum
  • the compounds of this invention were dissolved to a concentration of 177147 ng/ml as follows: Paclitaxel 5 % DMSO in full RPMI growth medium 5 5 % DMSO in full RPMI growth medium 8 5 % DMSO in full RPMI growth medium 11 5 % DMSO in full RPMI growth medium
  • the cells were stained for at least 15 min. with 0.4 % SRB, dissolved in 1 % acetic acid, and subsequently washed with 1 % acetic acid to remove the unbound stain.
  • the plates were air dried and the bound protein was dissolved by using 150 ⁇ l 10 mmol/l tris base.
  • the absorbance was read at 540 nm using an automatic microplate reader (Titertec, Flow Laboratories LtD., Irvine, Scotland). Data were used for construction of concentration-response curves and determination of the IC 50 -value.
  • the human tumor cell line OVCAR-3 was used.
  • OVCAR is an ovarium carcinoma.
  • paclitaxel or paclitaxel prodrugs were dissolved in DMSO to give a concentration of 5 mM. Concentrations were verified by measuring the OD at 226 nm. The antiproliferative effects of drugs and prodrugs were determined with the use of OVCAR-3 cells. Cells in supplemented tissue culture medium (DMEM, 10% fetal calf serum with 50 IU/ml penicillin and 50 microgram/ml streptomycin) were seeded in triplicate in 96-well culture plates (5000/well, 100 microliter). After 24 h, 100 microliter of culture medium containing drug or prodrug was added to give final concentrations ranging from 1 picomolar to 10 micromolar.
  • tissue culture medium fetal calf serum with 50 IU/ml penicillin and 50 microgram/ml streptomycin
  • IC 50 values are the (pro)drug concentrations that give 50% growth inhibition when compared with control cell growth (Houba et al. Bioconj. Chem. 1996, 7 , 606-611).
  • IC 50 values of the compounds of this invention are given in table II.
  • IC 50 (nM) Compound MCF7 EVSA-T WIDR IGROV M19 MEL A498 H226 OVCAR-3 paclitaxel ⁇ 3 ⁇ 3 ⁇ 3 33 ⁇ 3 5 ⁇ 3 0.25 5 ⁇ 3 ⁇ 3 ⁇ 3 ⁇ 3 3 39 10 - 6 ⁇ 3 ⁇ 3 ⁇ 3 233 ⁇ 3 ⁇ 3 ⁇ 3 0.80 8 69 59 167 49 311 436 241 - 11 390 300 589 241 1344 1435 706 -
  • Compound 5 showed similar cytotoxic activity as paclitaxel, which can probably be explained by the degradation of these compounds to the parent drug, under the conditions used to determine the activity.
  • the 2'-analog 5 is stable in PBS-buffer (pH 7.4). After 24 hours, only traces of paclitaxel were detected. Whereas in human plasma only after 20 hours 50 % of the analog is degraded to paclitaxel.
  • Compound 6 showed a comparable against OVCAR-3 cells, when compared to paclitaxel. Of compound 6 about 50% was degraded to paclitaxel within 4 hours. Furthermore, compound 6 is sixty times more watersoluble than paclitaxel.

Claims (4)

  1. Wasserlösliche, dem Paclitaxel analoge Antitumorverbindungen mit der nachstehenden Formel:
    Figure 00200001
    worin:
    R1 = C(O)CH2CH(OH)COOX
    R2 = H, C(O)CH2CH(OH)COOX,
    X = H, Li, Na oder irgendein anderes pharmazeutisch verträgliches Gegenion.
  2. Pharmazeutische Zusammensetzung, die eine antineoplastisch wirksame Menge der analogen Verbindung nach Anspruch 1 als Wirkstoff und einen pharmazeutisch verträglichen Träger, gegebenenfalls in Kombination mit weiteren Zusätzen, umfaßt.
  3. Verwendung einer wasserlöslichen, dem Paclitaxel analogen Antitumorverbindung nach Anspruch 1 für die Herstellung eines Medikaments zur Behandlung von Tumoren.
  4. Verwendung nach Anspruch 3, wobei der Tumor ein Mammakarzinom oder ein Kolontumor ist.
EP98940677A 1998-08-21 1998-08-21 Wasserlösliche ähnliche verbindungen und medicament-vorstufe von paclitaxel Expired - Lifetime EP1105379B1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL1998/000473 WO2000010988A1 (en) 1998-08-21 1998-08-21 Water soluble analogs and prodrugs of paclitaxel

Publications (2)

Publication Number Publication Date
EP1105379A1 EP1105379A1 (de) 2001-06-13
EP1105379B1 true EP1105379B1 (de) 2002-06-05

Family

ID=19866454

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98940677A Expired - Lifetime EP1105379B1 (de) 1998-08-21 1998-08-21 Wasserlösliche ähnliche verbindungen und medicament-vorstufe von paclitaxel

Country Status (11)

Country Link
US (1) US6344571B2 (de)
EP (1) EP1105379B1 (de)
JP (1) JP2002523407A (de)
AT (1) ATE218560T1 (de)
AU (1) AU8889998A (de)
CA (1) CA2341234A1 (de)
DE (1) DE69805860T2 (de)
DK (1) DK1105379T3 (de)
ES (1) ES2179526T3 (de)
PT (1) PT1105379E (de)
WO (1) WO2000010988A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414015B1 (en) 2000-01-28 2002-07-02 Utah State University Laulimalide microtubule stabilizing agents
AU2001270070B2 (en) 2000-06-22 2006-03-16 Nitromed, Inc. Nitrosated and nitrosylated taxanes, compositions and methods of use
US7212534B2 (en) 2001-07-23 2007-05-01 Broadcom Corporation Flow based congestion control
ITPD20020271A1 (it) 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
BRPI0608173A2 (pt) * 2005-02-24 2010-11-09 Elan Pharma Int Ltd composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo
WO2007075825A2 (en) * 2005-12-20 2007-07-05 Sonus Pharmaceuticals, Inc. Lipophilic anticancer drug compounds
CN101029034B (zh) * 2007-03-30 2010-05-26 浙江大学 多烯紫杉醇水溶性衍生物及制备方法和用途
CN106800542A (zh) * 2016-12-31 2017-06-06 辰欣药业股份有限公司 一种亲水性紫杉醇类化合物及其制备方法
CN108424405A (zh) * 2018-03-06 2018-08-21 华东师范大学 伏立诺他和紫杉醇的共前药及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
WO1994005282A1 (en) * 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives

Also Published As

Publication number Publication date
PT1105379E (pt) 2002-10-31
ATE218560T1 (de) 2002-06-15
US6344571B2 (en) 2002-02-05
US20010018531A1 (en) 2001-08-30
ES2179526T3 (es) 2003-01-16
DE69805860T2 (de) 2003-01-02
CA2341234A1 (en) 2000-03-02
WO2000010988A8 (en) 2000-06-15
EP1105379A1 (de) 2001-06-13
WO2000010988A1 (en) 2000-03-02
AU8889998A (en) 2000-03-14
DK1105379T3 (da) 2002-08-19
JP2002523407A (ja) 2002-07-30
DE69805860D1 (de) 2002-07-11

Similar Documents

Publication Publication Date Title
US5608087A (en) Water soluble taxol derivatives
US5278324A (en) Water soluble derivatives of taxol
US5352805A (en) Water soluble derivatives of taxol
US5411984A (en) Water soluble analogs and prodrugs of taxol
Mathew et al. Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity
Deutsch et al. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity
US5157049A (en) Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US4942184A (en) Water soluble, antineoplastic derivatives of taxol
US5614549A (en) High molecular weight polymer-based prodrugs
US5622986A (en) 2'-and/or 7-substituted taxanes
Damen et al. Paclitaxel esters of malic acid as prodrugs with improved water solubility
Du et al. Synthesis and evaluation of water-soluble docetaxel prodrugs-docetaxel esters of malic acid
CZ62094A3 (en) Paclitaxel derivatives bound onto a polymer
EP1105379B1 (de) Wasserlösliche ähnliche verbindungen und medicament-vorstufe von paclitaxel
Arpicco et al. Preparation and characterization of novel poly (ethylene glycol) paclitaxel derivatives
US5547981A (en) Taxol-7-carbazates
US8133888B2 (en) Hydrazide containing taxane conjugates
CA2397591C (en) Semi-synthetic taxanes with antitumor and antiangiogenetic activities
WO2001092245A1 (en) Novel paclitaxel derivatives for the treatment of cancer
JP4499383B2 (ja) 水溶性プロドラッグ
US20200147227A1 (en) Drug-bound compound and use thereof
Kapoor et al. Recent advances in structure modifications of Taxol (Paclitaxel)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 20010726

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REF Corresponds to:

Ref document number: 218560

Country of ref document: AT

Date of ref document: 20020615

Kind code of ref document: T

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69805860

Country of ref document: DE

Date of ref document: 20020711

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: NOVAGRAAF INTERNATIONAL SA

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20020402286

Country of ref document: GR

ET Fr: translation filed
REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20020725

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2179526

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20030306

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20080729

Year of fee payment: 11

Ref country code: NL

Payment date: 20080814

Year of fee payment: 11

Ref country code: LU

Payment date: 20080806

Year of fee payment: 11

Ref country code: ES

Payment date: 20080731

Year of fee payment: 11

Ref country code: DK

Payment date: 20080728

Year of fee payment: 11

Ref country code: DE

Payment date: 20080731

Year of fee payment: 11

Ref country code: CH

Payment date: 20080731

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20080731

Year of fee payment: 11

Ref country code: IT

Payment date: 20080808

Year of fee payment: 11

Ref country code: IE

Payment date: 20080728

Year of fee payment: 11

Ref country code: FR

Payment date: 20080731

Year of fee payment: 11

Ref country code: FI

Payment date: 20080731

Year of fee payment: 11

Ref country code: AT

Payment date: 20080731

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20080731

Year of fee payment: 11

Ref country code: CY

Payment date: 20080806

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20080731

Year of fee payment: 11

Ref country code: BE

Payment date: 20080730

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20080731

Year of fee payment: 11

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20100222

BERE Be: lapsed

Owner name: *PHARMACHEMIE B.V.

Effective date: 20090831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20100301

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20090821

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100222

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090821

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20100430

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090821

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090821

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100301

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090821

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100302

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20090822

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100303

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090821

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090821

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090821

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090822

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090822